Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
Authors
Keywords
-
Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-08-21
DOI
10.1002/anie.202109237
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2
- (2021) Guangyan Du et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials
- (2020) Atish Mohanty et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- FAK-targeting PROTAC as a chemical tool for the investigation of non-enzymatic FAK function in mice
- (2020) Hongying Gao et al. Protein & Cell
- Structural Insights into PROTAC-Mediated Degradation of Bcl-xL
- (2020) Chun-wa Chung et al. ACS Chemical Biology
- Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes
- (2020) James Schiemer et al. Nature Chemical Biology
- Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
- (2019) Maja J. A. de Jonge et al. Targeted Oncology
- Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions
- (2019) Johannes Popow et al. JOURNAL OF MEDICINAL CHEMISTRY
- SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate
- (2019) Michael J. Roy et al. ACS Chemical Biology
- A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
- (2019) Gabriel Mak et al. BRITISH JOURNAL OF CANCER
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs
- (2019) Hongying Gao et al. ACS Medicinal Chemistry Letters
- Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis
- (2018) Mikhail M. Savitski et al. CELL
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
- (2018) Philipp M. Cromm et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
- (2016) J. C. Soria et al. ANNALS OF ONCOLOGY
- Molecular Pathways: Endothelial Cell FAK--A Target for Cancer Treatment
- (2016) M. Roy-Luzarraga et al. CLINICAL CANCER RESEARCH
- Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors
- (2016) Timothy A. Marlowe et al. MOLECULAR CANCER THERAPEUTICS
- Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
- (2016) Hong Jiang et al. NATURE MEDICINE
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
- (2015) Alan Serrels et al. CELL
- A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors
- (2015) Suzanne F. Jones et al. INVESTIGATIONAL NEW DRUGS
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- Disrupting the Scaffold to Improve Focal Adhesion Kinase-Targeted Cancer Therapeutics
- (2013) W. G. Cance et al. Science Signaling
- Function of Focal Adhesion Kinase Scaffolding to Mediate Endophilin A2 Phosphorylation Promotes Epithelial-Mesenchymal Transition and Mammary Cancer Stem Cell Activitiesin Vivo
- (2012) Huaping Fan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors
- (2012) Jeffrey R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments
- (2010) Isabelle Tanjoni et al. CANCER BIOLOGY & THERAPY
- Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions
- (2010) M. D. Schaller JOURNAL OF CELL SCIENCE
- The FERM domain: organizing the structure and function of FAK
- (2010) Margaret C. Frame et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Small Molecule Chloropyramine Hydrochloride (C4) Targets the Binding Site of Focal Adhesion Kinase and Vascular Endothelial Growth Factor Receptor 3 and Suppresses Breast Cancer Growth in Vivo
- (2009) Elena V. Kurenova et al. JOURNAL OF MEDICINAL CHEMISTRY
- Nuclear FAK Promotes Cell Proliferation and Survival through FERM-Enhanced p53 Degradation
- (2008) Ssang-Taek Lim et al. MOLECULAR CELL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now